AN2 Therapeutics (ANTX) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Nkarta (NKTX) over the past year, gaining 254.8% versus a loss of 4.7%. AN2 Therapeutics is the larger company by market cap ($166.0 million vs $161.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | NKTX |
|---|---|---|
| Share price | $4.40 | $2.25 |
| Market cap | $166.04M | $161.16M |
| 1-day change | -5.98% | +1.35% |
| YTD return | +285.96% | +21.62% |
| 1-year return | +254.84% | -4.66% |
| 5-year return | — | -87.73% |
| EPS (TTM) | $-0.99 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $3.72 |
| 52-week low | $1.00 | $1.70 |
| Distance from 52-week high | -38.80% | -39.52% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +104.55% | +381.33% |
| Average volume | 240.21K | 602.17K |
| Shares outstanding | 37.74M | 71.62M |
| Employees | 21 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed NKTX by 259.5 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
ANTX vs NKTX FAQ
Which is bigger, AN2 Therapeutics or Nkarta?
AN2 Therapeutics (ANTX) is larger, with a market capitalization of $166.04M compared with $161.16M for Nkarta (NKTX).
Which stock has performed better over the past year, ANTX or NKTX?
ANTX returned +254.84% over the past 12 months, compared with -4.66% for NKTX (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.